Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. - Torka P; Akhtar OS; Reddy NM; Baysal BE; Kader A; Groman A; Nichols J; Mavis C; Tario JD; Block AW; Sait SNJ; Ghione P; et al. (Cancer, 2022)